Recent corporate updates from Ocugen highlight continuous operational progress across its gene therapy clinical trials, successful financial runway extensions ensuring cash support through upcoming milestones, and preparations for upcoming investor conference presentations. Leadership continues to prioritize advancing its late-stage OCU400 and OCU410 programs toward pivotal regulatory filings, while maintaining productive dialogues with health authorities regarding trial designs and rolling Biologics License Application submissions.